NCT06858956View on ClinicalTrials.gov

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER